Clinical Trial Update: Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis. [Phase 3]

View source ↗

Summary

A Phase 3 pediatric study is evaluating adverse events, changes in disease activity, and pharmacokinetics of oral upadacitinib in moderately to severely active …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• RINVOQ (Upadacitinib)
• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Ulcerative Colitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING